Goldman Sachs’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.97M | Buy |
489,637
+194,853
| +66% | +$1.98M | ﹤0.01% | 2805 |
|
|
2025
Q1 | $1.64M | Buy |
294,784
+24,778
| +9% | +$138K | ﹤0.01% | 3495 |
|
|
2024
Q4 | $2.18M | Sell |
270,006
-52,619
| -16% | -$425K | ﹤0.01% | 3414 |
|
|
2024
Q3 | $3.31M | Buy |
322,625
+43,815
| +16% | +$449K | ﹤0.01% | 3031 |
|
|
2024
Q2 | $1.97M | Buy |
278,810
+109,132
| +64% | +$772K | ﹤0.01% | 3201 |
|
|
2024
Q1 | $2.33M | Buy |
169,678
+118,890
| +234% | +$1.63M | ﹤0.01% | 3118 |
|
|
2023
Q4 | $467K | Buy |
50,788
+2,632
| +5% | +$24.2K | ﹤0.01% | 3988 |
|
|
2023
Q3 | $291K | Sell |
48,156
-8,014
| -14% | -$48.5K | ﹤0.01% | 4117 |
|
|
2023
Q2 | $436K | Sell |
56,170
-38,149
| -40% | -$296K | ﹤0.01% | 4045 |
|
|
2023
Q1 | $538K | Buy |
+94,319
| New | +$538K | ﹤0.01% | 4031 |
|
|
2022
Q4 | – | Sell |
-27,557
| Closed | -$88K | – | 5299 |
|
|
2022
Q3 | $88K | Sell |
27,557
-34,830
| -56% | -$111K | ﹤0.01% | 4952 |
|
|
2022
Q2 | $280K | Buy |
62,387
+2,081
| +3% | +$9.34K | ﹤0.01% | 4736 |
|
|
2022
Q1 | $322K | Buy |
60,306
+16,391
| +37% | +$87.5K | ﹤0.01% | 4846 |
|
|
2021
Q4 | $645K | Buy |
43,915
+3,494
| +9% | +$51.3K | ﹤0.01% | 4348 |
|
|
2021
Q3 | $845K | Buy |
40,421
+6,718
| +20% | +$140K | ﹤0.01% | 4098 |
|
|
2021
Q2 | $596K | Buy |
33,703
+7,383
| +28% | +$131K | ﹤0.01% | 4335 |
|
|
2021
Q1 | $645K | Buy |
26,320
+8,498
| +48% | +$208K | ﹤0.01% | 4194 |
|
|
2020
Q4 | $603K | Buy |
17,822
+4,278
| +32% | +$145K | ﹤0.01% | 3727 |
|
|
2020
Q3 | $339K | Buy |
13,544
+3,280
| +32% | +$82.1K | ﹤0.01% | 3838 |
|
|
2020
Q2 | $346K | Buy |
+10,264
| New | +$346K | ﹤0.01% | 3762 |
|